Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Lina Pugliano"'
Publikováno v:
Cancer Research. 83:P5-08
Background Breast cancer is the most commonly diagnosed cancer in Australia. Patient outcomes continue to improve with current 10 year survival of 86%. Given this, greater focus is needed to minimise potential long term toxicities of prescribed thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9266d7e810aca8d0b4ebd4ef7c30c7e1
https://doi.org/10.1158/1538-7445.sabcs22-p5-08-17
https://doi.org/10.1158/1538-7445.sabcs22-p5-08-17
Autor:
Anna Boltong, Alexis Butler, Barbara S. van der Meij, Tracey Nicholls, Rebecca Fichera, Elizabeth Isenring, Jenelle Loeliger, Judy Bauer, Tina L. Skinner, Irene Deftereos, Jane Stewart, Sandi Hayes, Brenton J. Baguley, Michelle Eisenhuth, Emily Jeffery, Steve F. Fraser, Lina Pugliano, Nicole Kiss, Carolyn McIntyre, Catherine Johnson, Hayley Griffin, Merran Findlay, Chris Lomma
Publikováno v:
Nutrition & Dietetics
Nutrition & Dietetics: Journal of Dietitians Australia, 77, 416-425
Nutrition & Dietetics: Journal of Dietitians Australia, 77, 416-425
This position statement describes the recommendations of the Clinical Oncology Society of Australia (COSA) regarding management of cancer‐related malnutrition and sarcopenia. A multidisciplinary working group completed a review of the literature, f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6214af0fe76b8f49f8eb674b4eb0f95
http://europepmc.org/articles/PMC7540290
http://europepmc.org/articles/PMC7540290
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 12:5-15
Aim: Treatment with pertuzumab-trastuzumab-taxane combinations has become the international standard of care for patients with HER2-positive metastatic breast cancer. In this paper we discuss the practicalities of treating patients with this combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4c3927ccfd000a6b6a44b8dd11c50a5
https://doi.org/10.1111/ajco.12500
https://doi.org/10.1111/ajco.12500
Publikováno v:
memo - Magazine of European Medical Oncology. 6:158-166
The National Cancer Institute of the United States defines personalized medicine (PM) as “a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease” (National Cancer Institu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d18dcf508a078bd159192e8d790a91aa
https://doi.org/10.1007/s12254-013-0104-x
https://doi.org/10.1007/s12254-013-0104-x
Publikováno v:
Asia-Pacific journal of clinical oncology. 12
Treatment with pertuzumab-trastuzumab-taxane combinations has become the international standard of care for patients with HER2-positive metastatic breast cancer. In this paper we discuss the practicalities of treating patients with this combination w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d3577a056b49b77898ddb7c02c6aa63f
https://pubmed.ncbi.nlm.nih.gov/27250913
https://pubmed.ncbi.nlm.nih.gov/27250913
Autor:
Lina Pugliano, Felipe Ades, Evandro de Azambuja, Marta Capelan, Ivana Bozovic-Spasojevic, Dimitrios Zardavas
Publikováno v:
Breast Cancer Management. 1:217-233
SUMMARY HER2 positivity defines a molecular subtype of breast cancer with aggressive biological behavior. HER2 has been clinically validated as a prominent therapeutic target in breast cancer, and an abundance of data from clinical trials proving the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae5da895cbcbe910d8bd619258f5f812
https://doi.org/10.2217/bmt.12.35
https://doi.org/10.2217/bmt.12.35
Publikováno v:
Current Opinion in Oncology. 23:547-558
PURPOSE OF REVIEW: There have been recent new developments in the treatment of breast cancer that over-expresses HER2 (ERRB2/HER2 positive) and the mechanistic understanding of trastuzumab response. We review these findings and reflect on how they ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa127c346db03d113a779ddc6b1bbf28
https://doi.org/10.1097/cco.0b013e32834bd4c9
https://doi.org/10.1097/cco.0b013e32834bd4c9
Autor:
Evandro de Azambuja, Lina Pugliano
Publikováno v:
Onkologie. 35:476-478
(range 9–53%) with a median OS of 11.0 months (range 5.3– 18.1 months). The advantages of capecitabine are well documented and include good efficacy, tolerability with minimal grade 3–4 toxicity, oral preparation, maintaining quality of life, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6265a8489a71dc3d297147c21166f867
https://doi.org/10.1159/000342209
https://doi.org/10.1159/000342209
Autor:
Anca, Bucur, Jasper, Van Leeuwen, Njin-Zu, Chen, Brecht, Claerhout, Kristof, De Schepper, David, Perez-Rey, Raul, Alonso-Calvo, Lina, Pugliano, Kamal, Saini
Publikováno v:
Studies in health technology and informatics. 205
To support the efficient execution of post-genomic multi-centric clinical trials in breast cancer we propose a solution that streamlines the assessment of the eligibility of patients for available trials. The assessment of the eligibility of a patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8e7a745aec77a0cef333cdb4cfbba4b5
https://pubmed.ncbi.nlm.nih.gov/25160302
https://pubmed.ncbi.nlm.nih.gov/25160302
Autor:
Marianne Paesmans, I.B. Spasojevic, Lina Pugliano, Martine Piccart, M. Capelan, Felipe Ades, Dimitrios Zardavas, E. de Azambuja
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 25(8)
Background: To explore the current clinical management of early-stage breast cancer (BC) patients, identify areas of controversy, and interrogate how treating physicians implement latest advances. Methods: We conducted a 27-item survey, disseminated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c1311f34eab2be7c2539b10deb35fe7
https://pubmed.ncbi.nlm.nih.gov/24562450
https://pubmed.ncbi.nlm.nih.gov/24562450